Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
Publication Name: Breast Cancer Research and Treatment
Background Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negative patients … Continued